Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 11/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 11/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771315 | 0.90 | PLG (0.51) | KDM4EALDH1A1MMP13MMP9MMP2 | |
| SCHEMBL6767876 | 0.85 | ALDH1A1 (0.49) | KDM4EALDH1A1MMP13MMP1MMP9 | |
| SCHEMBL6767808 | 0.75 | MMP1 (0.45) | KDM4EALDH1A1MMP13MMP1MMP9 | |
| SCHEMBL6767630 | 0.75 | MMP1 (0.45) | KDM4EALDH1A1MMP13MMP1MMP9 | |
| SCHEMBL23693571 | 0.75 | AHR (0.53) | KDM4EALDH1A1BCAT1AHR | |
| SCHEMBL29886879 | 0.75 | AHR (0.53) | KDM4EALDH1A1BCAT1AHR | |
| SCHEMBL6770871 | 0.74 | MMP1 (0.44) | KDM4EALDH1A1MMP13MMP1MMP9 | |
| SCHEMBL6773578 | 0.74 | MMP1 (0.44) | KDM4EALDH1A1MMP13MMP1MMP9 | |
| SCHEMBL23673449 | 0.73 | AHR (0.54) | BCAT1AHR | |
| SCHEMBL6771399 | 0.72 | ALDH1A1 (0.51) | KDM4EALDH1A1MMP13BCAT1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210326-B1 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-25 | — | — | EP | claimed |
| US-6677355-B1 | DIBENZOFURAN-3-(SULFONYLAMINO OR SULFINAMINO) DERIVATIVES; MULTIPLE SCLEROSIS, ATHEROSCLEROSIS, HEART FAILURE, PERIODONTAL DISEASE, OSTEOARTHRITIS, AUTOIMMUNE DISEASE; ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2004-01-13 | — | — | US | claimed |
| EP-1210326-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001012592-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-22 | — | — | WO | claimed |
| EP-1210326-B1 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6677355-B1 | DIBENZOFURAN-3-(SULFONYLAMINO OR SULFINAMINO) DERIVATIVES; MULTIPLE SCLEROSIS, ATHEROSCLEROSIS, HEART FAILURE, PERIODONTAL DISEASE, OSTEOARTHRITIS, AUTOIMMUNE DISEASE; ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2004-01-13 | — | — | US | disclosed |
| EP-1210326-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012592-A2 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-22 | — | — | WO | disclosed |